J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

John­son & John­son said that its com­bi­na­tion treat­ment staved off can­cer pro­gres­sion for longer than As­traZeneca’s block­buster Tagris­so as a first op­tion for pa­tients with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER